Central South University

csu.edu.cn

Total trials

120

Active

21

Phase 3

3

Total enrollment

649,797

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 11 of 11 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Jieyu Chufan1
Jieyu Chufan Capsules simulant1
individualized vancomycin dosing based on the population pharmacokinetics (PK) model1
empirical vancomycin dosing1
Atorvastatin1
Metformin treatment1
metformin7
AKK1
Escitalopram2
Aripiprazole 5mg1
160 units nasal insulin spray1

Next readouts

  • 2024-12
  • 2024-12-31
  • 2026-04-08
  • 2026-12-12
  • 2026-12-20
  • 2026-12-31
  • 2027-12-31

Top conditions

  • Schizophrenia26
  • Bipolar Disorder6
  • Depression5
  • Major Depressive Disorder4
  • Major Depressive Disorder (MDD)3
  • Aortic Dissection3
  • Parkinson Disease3
  • Low Back Pain2

Frequently asked questions about Central South University

How many clinical trials does Central South University have on ClinicalTrials.gov?
Central South University is listed as the lead sponsor on 120 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
How many of Central South University's trials are in Phase 3?
3 of Central South University's trials are in Phase 3, spread across 11 active drug programs.
What therapeutic areas does Central South University focus on?
Central South University's most-studied conditions on ClinicalTrials.gov are Schizophrenia, Bipolar Disorder, Depression, Major Depressive Disorder, Major Depressive Disorder (MDD).
When are Central South University's next clinical trial readouts?
Central South University has 7 upcoming primary-completion readouts tracked here; the soonest is “Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model”, expected around 2024-12.